Fig. 1: GCDFP in ER+ breast carcinoma.
From: Novel uses of immunohistochemistry in breast pathology: interpretation and pitfalls
Nearly all ER+ breast carcinomas, especially those with low- to intermediate-grade histology (A, B) and strong, diffuse ER labeling (C), will label for GCDFP (cytoplasmic) (D), mammaglobin (not shown), and GATA3 (not shown).
